Accès ouvert
2026
article
OpenAlex
Gabriela Ananieva, Cédric Vancaeyzeele, Giao Nguyen, Frédéric Vidal et autres
ABSTRACT Herein, we report a biofriendly, air‐operating electrochemical platform based on a unipolar coiled carbon nanotube (CNT) yarn artificial muscle that can operate either as an ionic actuator or as an ionotronic strain sensor. The device comprises two coiled CNT yarn electrodes …
fr, se, nl
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Giorgio Limoncella, Anna Girardi, Claudia Bartolini, Giulia Hyeraci et autres
PURPOSE: In 2019, the Innovative Medicines Initiative funded the ConcePTION project to enhance monitoring of medication safety in pregnancy and breastfeeding. This paper describes how the ConcePTION Pregnancy Algorithm (PA) identified pregnancies in 10 diverse European electronic healthcare data sources and estimated …
it, es, nl, us, fr, gb, no, Maroc, ie, dk
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Ana Sofía Afonso, Krista Schroeder, Lucy Mitchell, Natacha Carragher et autres
OBJECTIVES: To characterise demographics, comorbidities, co-medications and healthcare resource utilisation (HCRU) in patients newly diagnosed with Alzheimer's disease (AD) in England using published and validated AD algorithms. DESIGN: Observational cohort study. SETTING: Real-world data in England from the Clinical Practice Research Datalink …
nl, us, gb, ie
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Timothy F. Burns, Yutaka Fujiwara, Victor T. G. Lin, Marcelo V. Negrão et autres
8570 Background: Real-world data suggests allowing 1 cycle of standard of care (SOC) prior to enrollment into first-line (1L) NSCLC trials of targeted therapies could expand the potential enrollable population by accommodating molecular testing turnaround time and enabling a more representative patient …
us, jp, es, ch, nl
(code pays fourni par la source)
Accès ouvert
2026
conference-abstract
OpenAlex
Bryan Chan, Solange Peters, L León, T Yamada et autres
8628 Background: For patients (pts) with 1L KRAS G12C-mutant advanced NSCLC and PD-L1 expression <50%, the current SOC is pembrolizumab + platinum-based chemotherapy. Combining olomorasib, a KRAS G12C inhibitor, with pembrolizumab may overcome the limited efficacy of single-agent pembrolizumab in this population, …
au, ch, es, jp, us, tw, gr, cz, de, ca, nl
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Scott B. Vafai, Jörg Täubel, Thomas Ashdown, Riyaz S. Patel et autres
BACKGROUND: in the liver. METHODS: -acetylgalactosamine. The objectives were to assess safety and changes in blood PCSK9 protein and LDL cholesterol levels. RESULTS: A total of 35 participants across the six dose cohorts received VERVE-102 and had at least 28 days of …
nl, gb, ca, au
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Luis León‐Mateos, M. Hochmair, Amparo Sánchez-Gastaldo, Audrey Rabeau et autres
INTRODUCTION: The single-arm phase 1/2 LIBRETTO-001 trial demonstrated durable efficacy and a favorable safety profile with the selective RET inhibitor (RETi) selpercatinib in patients with RET fusion-positive non-small cell lung cancer (NSCLC), regardless of prior non-RET-selective treatment. The aim of this study …
es, fr, de, us, nl
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Kazuto NISHIO, Kazuko SAKAI, Makoto Nishio, Takashi SETO et autres
Introduction: mutation subtypes. Methods: mutation subgroups (ex19del; L858R). Results: 0.0001) and was sustained to follow-up in the RAM plus ERL arm within the L858R subgroup only. cfDNA fragment size decreased from baseline to cycle 4 in the RAM plus ERL arm within …
jp, nl, us
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Wan‐Shan Li, Meng-Yun Hung, Yu‐Hsuan Kuo, Shu‐Farn Tey et autres
PURPOSE Next-generation sequencing is optimal for testing advanced/metastatic non–small cell lung cancer (NSCLC) biomarkers; however, implementation and access are often hindered across Asia by turnaround time (TAT), logistics, and reimbursement. This study aimed to implement a multigene biomarker testing algorithm for the …
tw, nl
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Makoto Nishio, Takashi Seto, M. Reck, E.B. Garon et autres
Introduction: -mutated NSCLC. We report the final overall survival (OS) and safety. Methods: T790M mutation. Patients received RAM (10 mg/kg every 2 wk) plus GEF (250 mg once daily) until disease progression (period 1); patients with disease progression who acquired a T790M …
jp, de, fr, in, us, nl
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Kazumi Nishino, Takashi Seto, Makoto Nishio, Kazuto Nishio et autres
Aim The global phase III RELAY trial demonstrated the efficacy of ramucirumab (RAM) plus erlotinib (ERL) in patients with untreated metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). We present safety and efficacy profiles of RAM+ERL in Japanese elderly …
jp, in, nl
(code pays fourni par la source)
Accès ouvert
2025
review
OpenAlex
Melanie H. Jacobson, Meritxell Sabidó, Ana Sofía Afonso, Adebola Ajao et autres
INTRODUCTION: Major congenital malformations (MCMs) are a primary outcome of interest in pregnancy safety studies. OBJECTIVE: This study aimed to identify and summarize algorithms used to identify MCMs in routinely collected healthcare data sources in the USA, Canada, and Europe by conducting …
us, de, nl, sa, fr, ie, dk
(code pays fourni par la source)